Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm
- PMID: 9850135
- DOI: 10.1093/oxfordjournals.aje.a009590
Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm
Abstract
In this paper, the authors present an evaluation algorithm for systematic assessment of the observed heterogeneity in disease risk within trial populations. Predictive models are used to estimate the predicted patient hazards, the odds of having an event in the upper risk quartile (ODU) and the lower risk quartile (ODL), and the odds ratio (rate ratio for time-to-event analyses) for having an event in the upper risk quartile versus the lower risk quartile (extreme quartile odds ratio (EQuOR) and extreme quartile rate ratio (EQuRR)). The ranges for these metrics depend on the extent to which predictors of the outcome of interest exist and are known and the extent to which data are collected in the trial, as well as on the eligibility criteria and the specific patients who are actually enrolled. ODU, ODL, and EQuOR values are used to systematically interpret the results for patients at different levels of risk, to evaluate generalizability, and to determine the need for subgroup analyses. Individual data for five outcomes from three trials (n = 842, 913, and 1,001, respectively) are used as examples. Observed EQuOR values ranged from 1.5 (very little predicted heterogeneity) to 59 (large heterogeneity). EQuRR values ranged from 2 to 46. ODU values ranged from 0.24 to 3.19 (generally high risk), and ODL values ranged from 0.01 (clinically negligible risk) to 0.16 (clinically meaningful risk). The algorithm may also be used for comparing diverse trials (e.g., in meta-analyses) and used prospectively for designing future trials, as shown in simulations.
Similar articles
-
Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data.J Clin Epidemiol. 2001 Mar;54(3):245-52. doi: 10.1016/s0895-4356(00)00311-5. J Clin Epidemiol. 2001. PMID: 11223322
-
Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.Arch Intern Med. 1992 Oct;152(10):2009-13. Arch Intern Med. 1992. PMID: 1417373
-
Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone.N Engl J Med. 1990 Sep 20;323(12):776-82. doi: 10.1056/NEJM199009203231202. N Engl J Med. 1990. PMID: 2392131 Clinical Trial.
-
Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.Expert Rev Anti Infect Ther. 2017 Sep;15(9):873-892. doi: 10.1080/14787210.2017.1364991. Epub 2017 Aug 21. Expert Rev Anti Infect Ther. 2017. PMID: 28782390 Review.
-
[Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].Klin Padiatr. 2001 Sep;213 Suppl 1:A38-49. doi: 10.1055/s-2001-17501. Klin Padiatr. 2001. PMID: 11577363 Review. German.
Cited by
-
An aseptically processed, acellular, reticular, allogenic human dermis improves healing in diabetic foot ulcers: A prospective, randomised, controlled, multicentre follow-up trial.Int Wound J. 2018 Oct;15(5):731-739. doi: 10.1111/iwj.12920. Epub 2018 Apr 22. Int Wound J. 2018. PMID: 29682897 Free PMC article. Clinical Trial.
-
Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence.Int J Epidemiol. 2016 Dec 1;45(6):2184-2193. doi: 10.1093/ije/dyw125. Int J Epidemiol. 2016. PMID: 27864403 Free PMC article.
-
From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer.BMC Med Res Methodol. 2012 Dec 13;12:185. doi: 10.1186/1471-2288-12-185. BMC Med Res Methodol. 2012. PMID: 23234603 Free PMC article. Review.
-
The relative merits of population-based and targeted prevention strategies.Milbank Q. 2008 Dec;86(4):557-80. doi: 10.1111/j.1468-0009.2008.00534.x. Milbank Q. 2008. PMID: 19120980 Free PMC article.
-
Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model.Am J Med. 2018 Jun;131(6):676-683.e2. doi: 10.1016/j.amjmed.2017.12.010. Epub 2017 Dec 25. Am J Med. 2018. PMID: 29284111 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources